Marriage Counselors in Mount Laurel, NJ Accepting Medicare

4 Marriage Counselors found. Showing 1 - 4

Diane Fabii, MS Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 2404 Rogers Walk, Mount Laurel, NJ 08054 Phone: 856-313-5585

Ms. Dawn Marie Lacy, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 114 Yorktown Dr, Mount Laurel, NJ 08054 Phone: 609-233-4208

Mrs. Alicia Yvette Haynes-belford, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 10000 Midlantic Dr Ste 101e, Mount Laurel, NJ 08054 Phone: 732-978-9892

Theresa P Jahn, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 237 Willow Turn # A, Mount Laurel, NJ 08054 Phone: 908-477-7242

News Archive

Serotonin instructs scar forming cells to switch off regeneration in chronic liver disease

In liver disease, extent of tissue damage depends on the balance between the generation of scar tissue and the regeneration of new liver cells. In a significant minority of people who get injury to their organs instead of repairing them, they form scars.

Researchers discover new gene associated with aortic aneurysms

An interdisciplinary team of researchers has identified a new gene linked to human aortic aneurysms. By combining comprehensive genetic studies in the fruit fly, dataset searches and analysis of diseased human aortic tissue, the researchers shed light on mechanisms not previously known to be associated with this devastating disease.

Researchers identify potential drug target to fight TB

The U.S. Food and Drug Administration recently approved the first new drug to fight tuberculosis (TB) in more than 40 years, but treatment still takes six months, 200 pills and leaves 40 percent of patients uncured. Thus, new targets are needed. Today in ACS Central Science, researchers report they have identified one such target - a gene that allows the disease to camp out in human immune cells, and is thus essential for the organism's proliferation.

Amgen to reduce price of Neulasta following Board's orders

The Board issued a Notice of Hearing on March 16, 2009, pertaining to allegations of Board Staff that Neulasta had been, and was being, sold by Amgen Canada Inc. at prices exceeding those indicated by the Board's Excessive Price Guidelines. On October 13, 2009, the Hearing Panel received a Joint Submission by Amgen and Board Staff along with a Voluntary Compliance Undertaking ("VCU") which proposed to resolve the issues raised in the Neulasta proceedings.

Read more Medical News

› Verified 6 days ago